The new study suggested that the inhibition of cyclin E1 by the cyclin-dependent kinase inhibitors dinaciclib and alvocidib (flavopiridol) could suppress HCC cell growth by inducing apoptosis and enhance the killing function of regorafenib and sorafenib in vitro and vivo [89]. The gene discussed is CCNE1; the disease is hepatocellular carcinoma.